{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003931","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.819811+00:00","generated_at":"2026-06-07T02:33:09.611192+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vera Therapeutics appoints new CMO and CDO; prior CMO departed","bullets":["Dr. Celia Lin separated as CMO effective Jan 3, 2024; received target 2023 bonus and severance.","Dr. Robert Brenner appointed CMO effective Jan 3, 2024; brings 25+ yrs nephrology and biotech experience.","William D. Turner appointed CDO effective immediately; led drug development, NDA/MAA filings at Sierra and Aimmune.","Both execs to support atacicept Phase 3 trial in IgA nephropathy and pipeline development."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003931","json":"https://secwatch.observer/filing/0001193125-24-003931.json","markdown":"https://secwatch.observer/filing/0001193125-24-003931.md","text":"https://secwatch.observer/filing/0001193125-24-003931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312524003931/0001193125-24-003931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312524003931/d110151d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:33:09.611192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bac7e27f26","claim":"Celia Lin departed as Chief Medical Officer at Vera Therapeutics, Inc..","evidence_excerpt":"On January 8, 2024, Vera Therapeutics, Inc. (the \"Company\") announced that Celia Lin, M.D., the Company’s Chief Medical Officer, had separated from the Company effective January 3, 2024 (the \"Separation Date\").","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831828/000119312524003931/0001193125-24-003931-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"separated"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"d77773e650","claim":"Robert M. Brenner was appointed as Chief Medical Officer at Vera Therapeutics, Inc..","evidence_excerpt":"The Company appointed Dr. Robert M. Brenner, M.D., to succeed Dr. Lin as the Company’s Chief Medical Officer, effective January 3, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831828/000119312524003931/0001193125-24-003931-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}